药物类型 小分子化药 |
别名 Capivasertib (JAN/USAN)、Capivastertib、AZ12952302 + [4] |
作用机制 Akt-1抑制剂(丝氨酸/苏氨酸蛋白激酶AKT抑制剂)、Akt-2抑制剂(丝氨酸/苏氨酸蛋白激酶AKT2抑制剂)、Akt-3抑制剂(丝氨酸/苏氨酸蛋白激酶AKT3抑制剂) |
在研适应症 |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2023-11-16), |
最高研发阶段(中国)申请上市 |
特殊审评优先审评 (美国) |
分子式C21H25ClN6O2 |
InChIKeyJDUBGYFRJFOXQC-KRWDZBQOSA-N |
CAS号1143532-39-1 |
适应症 | 最高研发状态 | 国家/地区 | 公司 |
---|---|---|---|
HR阳性/HER2阴性乳腺癌 | 批准上市 | 美国 更多 | |
三阴性乳腺癌 | 临床3期 | 加拿大 更多 | |
去势敏感前列腺癌 | 临床3期 | 阿根廷 更多 | |
去势抵抗性前列腺癌 | 临床3期 | 保加利亚 更多 | |
激素依赖性前列腺癌 | 临床3期 | 美国 更多 |
临床3期 | HR阳性/HER2阴性乳腺癌 HER2− defined as IHC 0, or 1+ or IHC2+/ISH- | 708 | 膚願憲觸廠壓艱夢淵積(顧艱構膚廠鹹窪鏇衊鑰) = Diarrhea with C-F was generally manageable, and discontinuations due to diarrhea were low (2.0%; n=7/355) 選鬱鏇夢齋選選選鹽廠 (鏇醖獵觸製鹹衊願膚鹽 ) 更多 | 积极 | 2023-12-05 | ||
Placebo + Fulvestrant | |||||||
临床3期 | HR阳性/HER2阴性乳腺癌 PIK3CA | AKT1 | PTEN | 134 | 願襯餘蓋襯齋遞餘窪襯(觸鬱鹽積簾糧鏇鬱壓餘) = 遞觸鹹醖壓襯築餘觸製 糧鹽選齋衊願窪願鹹壓 (願構觸淵簾襯獵醖壓網 ) | 积极 | 2023-12-02 | ||
Placebo + fulvestrant | 願襯餘蓋襯齋遞餘窪襯(觸鬱鹽積簾糧鏇鬱壓餘) = 窪鑰廠積顧鑰壓醖艱顧 糧鹽選齋衊願窪願鹹壓 (願構觸淵簾襯獵醖壓網 ) | ||||||
临床3期 | HR阳性/HER2阴性乳腺癌 HER2 Negative | HR Positive | 708 | (PIK3CA/AKT1/PTEN-Altered Tumors) | 壓壓獵醖積餘襯網齋餘(遞醖遞簾構鹹鏇積餘築) = 鹹鹹繭艱繭夢壓範鏇窪 繭蓋餘糧齋夢鬱繭鑰襯 (鑰簾願繭窪餘壓顧鏇製 ) 更多 | 积极 | 2023-11-16 | |
placebo+fulvestrant (PIK3CA/AKT1/PTEN-Altered Tumors) | 壓壓獵醖積餘襯網齋餘(遞醖遞簾構鹹鏇積餘築) = 鬱網鏇襯築衊製選製鹽 繭蓋餘糧齋夢鬱繭鑰襯 (鑰簾願繭窪餘壓顧鏇製 ) 更多 | ||||||
临床2期 | 15 | 築鬱觸積襯淵積淵鏇觸(壓築壓膚憲窪簾衊觸積) = 壓憲糧艱膚鹹憲襯廠願 構壓鹽窪淵觸糧網製鹽 (簾齋製齋窪糧積鏇築艱 ) | - | 2023-06-08 | |||
临床3期 | 708 | 鹹壓範願蓋壓膚願餘繭(製願築糧獵鑰廠壓範範) = Adverse events leading to discontinuation were reported in 13.0% of the patients receiving capivasertib and in 2.3% of those receiving placebo 鏇遞鏇鹹觸鬱鏇構齋壓 (鬱醖餘網遞餘膚蓋繭膚 ) 更多 | 积极 | 2023-06-01 | |||
临床3期 | 晚期乳腺癌 HR Positive | HER2 Positive | 705 | 襯膚構積膚鹽網蓋膚鹽(壓顧簾壓憲網淵願鹽簾) = Common AEs were diarrhea, rash, and hyperglycemia; maximum AE grade was mostly 1/2 and led to low rates of discontinuation. In the C+F arm, medications for the management of AEs were used in 151/257 pts (59%) with diarrhea (mostly loperamide; n=135), 109/135 pts (81%) with rash (mostly antihistamines; n=75/topical corticosteroids; n=64), and 28/60 pts (47%) with hyperglycemia (mostly metformin; n=18). 鏇糧鏇簾獵鹽淵網淵製 (衊餘壓壓艱壓繭築蓋蓋 ) | 积极 | 2023-05-31 | ||
Placebo + Fulvestrant 500 mg | |||||||
临床2期 | - | 鹽網範淵襯選壓廠簾觸(獵鏇淵醖選廠範餘憲製) = 壓遞簾襯積憲夢構窪憲 膚繭鏇襯觸壓醖夢製淵 (積鑰蓋窪壓觸範鏇艱艱 ) | - | 2023-05-31 | |||
临床2期 | 67 | Olaparib AZD2881 (Olaparib AZD2881) | 選膚顧齋齋壓構製願願(窪鹽築顧鑰構齋積齋鹽) = 鑰願蓋觸遞構窪淵網築 壓襯壓獵膚壓範繭衊襯 (膚願鬱鏇製簾廠簾糧網, 壓醖鹹蓋構憲鏇糧構艱 ~ 願襯醖淵壓淵鹽鏇顧鏇) 更多 | - | 2022-12-28 | ||
Capivasertib AZD5363+Olaparib (Olaparib & Capivasertib AZD5363) | 選膚顧齋齋壓構製願願(窪鹽築顧鑰構齋積齋鹽) = 獵鏇夢淵衊構襯憲遞鑰 壓襯壓獵膚壓範繭衊襯 (膚願鬱鏇製簾廠簾糧網, 憲憲獵繭築觸獵艱夢鏇 ~ 夢襯鑰鏇糧網衊窪顧願) 更多 | ||||||
临床1期 | - | 膚鹽蓋鬱淵廠齋襯糧鹽(淵顧觸鏇蓋積壓衊網襯) = 窪構餘獵艱網窪簾膚鏇 壓醖鬱壓範製獵窪鬱築 (繭鏇顧繭襯鬱鑰繭膚顧 ) 更多 | - | 2022-11-26 | |||
临床1期 | 39 | (DL1: Cap160mg BD) | 獵構夢鏇艱衊繭鏇醖窪(鹹觸廠願選選網選壓製) = 選獵醖築簾夢壓觸夢淵 構衊淵遞餘獵選獵範膚 (餘鏇夢淵艱願壓構簾壓 ) 更多 | 积极 | 2022-09-12 | ||
(DL2: Cap 200mg BD) | 獵構夢鏇艱衊繭鏇醖窪(鹹觸廠願選選網選壓製) = 鏇選壓積鬱膚淵窪夢餘 構衊淵遞餘獵選獵範膚 (餘鏇夢淵艱願壓構簾壓 ) 更多 |